JKJohn F. Kurtzke

John F. Kurtzke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John F. Kurtzke has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • On the Epidemiology of Multiple Sclerosis in the Middle East and North Africa

    by John F. Kurtzke

    Professor Sahraian and his colleagues from Tehran, Iran, have presented a unique summation of the developing evolution of the epidemiology of multiple sclerosis (MS) in a region of growing importance, and a region about which most of us have little awareness [1 ](Neuroepidemiology in press). The trend of the prevalence of MS with a high frequency in the north and with a low frequency in the south has long disappeared from Europe and has been reducing in the Americas as well. Citing recent scattered reports suggesting that regions of the Middle East and North Africa, situated largely between the 15th and 25th parallels of latitude, may also be joining in this trend of increasing MS, they have analyzed all relevant publications that appeared between January 1, 1985 and August 1, 2014; 52 such reports were included in their analysis.


  • Epidemiology in multiple sclerosis: a pilgrim’s progress

    by John F. Kurtzke

    There was more neurology taught under Harold G. Wolff at Cornell University Medical College in New York than perhaps anywhere else in the country when I attended from 1948 to 1952. I took my residency at the Veterans Administration Hospital in the Bronx, New York, a teaching hospital of Cornell, with Wolff as my Director of Training. While a resident, we thought we had found a treatment for multiple sclerosis. To test our conclusion, the first Class 1 treatment trial ever conducted for multiple sclerosis was performed. This showed no effect, but the participants began investigating multiple sclerosis among the 16 million persons at prime age for symptom onset who had served in the military in World War II. This led me to study its epidemiology worldwide, beginning with a detailed review of all published population-based estimates of frequency. Among these were nationwide surveys from Sweden, Denmark, Switzerland and later Norway and Finland, which showed in each country a concentration of the significantly high regions into contiguous areas forming a single 'focus' in each land, maximal in Denmark under the age of 15 years. The primary locus of high frequency multiple sclerosis seemed to be in the south-central inland lake region of Sweden, with spread to its contiguous neighbours. These concentrations in time and space indicated that multiple sclerosis was a disease probably acquired in early adolescence. Migration studies supported this: moves from high to low showed retention of birthplace risk only for those aged >15 years, whereas opposite moves indicated susceptibility limited to some 11-45 year olds. Epidemics of multiple sclerosis would suggest the disease is not only acquired but also infectious. If an infectious origin were true, transmission would have to occur before clinical onset, and would have to involve a much greater number of subjects than clinically involved. I believe there have been epidemics in Iceland, Shetland-Orkney and the Faroe Islands. On the Faroes there were no cases of multiple sclerosis among native-born resident Faroese from 1900 until 1943, when the first of 21 cases had clinical onset, heralding a type 1 epidemic with peak incidence rates >10 per 100,000 for 1945-46. British troops who occupied the islands from April 1940 to September 1945 we believe brought a widespread (because of the scatter of Faroese cases), asymptomatic (because they were healthy troops), persistent infection we called the primary multiple sclerosis affection that involved a large proportion of Faroese, with clinical multiple sclerosis ensuing in a very small proportion. Primary multiple sclerosis affection itself may have been manifest there as a newly introduced cause of acute infectious gastroenteritis and is possibly the underlying cause of multiple sclerosis in general.


  • Migration and multiple sclerosis in United Kingdom and Ireland immigrants to Australia: a reassessment. II. Characteristics of early (pre-1947) compared to later migrants

    by J. G. McLeod, S. R. Hammond, J. F. Kurtzke

    In our recent reassessment we explored the risk of MS by age at immigration in 258 migrants from United Kingdom and Ireland (UKI) to four states of Australia (New South Wales, Queensland, South Australia, and Western Australia) in the period 1947–1981 (Group II). In the present report we have compared their characteristics with 44 cases who migrated before 1947 (Group I), divided into two subsets: Group Ia (15 cases) was rather similar to Group II in age at immigration (means of 20 and 23 years), age at onset (39 and 33 years), and duration from immigration to onset (19 and 10 years). Group Ib (29 cases) was significantly different from Group II, with mean ages of 4 years at immigration and 40 years at onset, for a mean interval of some 35 years between immigration and onset. All onsets in Group Ib occurred after 1947. We concluded that the Group Ib cases had most probably acquired their MS in Australia. Immigrants from high MS risk countries, including UKI, were modest in number before 1947, but some 770,000 entered from 1947–1981. They may have been the source of MS for the Group Ib migrants.


  • Open Access

    Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration

    by J. G. McLeod, S. R. Hammond, J. F. Kurtzke

    A previous study of the prevalence of multiple sclerosis (MS) in 1981 among immigrants from the United Kingdom and Ireland to Australia found that the prevalence for those with age at immigration (AAI) under 15 years of age did not differ from the older immigrants. We have reanalysed the original materials as well as census data for 1901–1981 for UKI and other high MS risk country immigrants. There was a highly significant trend in the prevalence rates of all Australians from New South Wales (NSW) to South Australia (SA) to Western Australia (WA) to Queensland (QLD). Rates by state among the Australian-born were almost identical to these, but there was no prevalence gradient for the UKI-born. The denominator population at risk of MS by AAI was calculated from special census tables of length of residence in Australia by age 0–79 in 1981 for UKI immigrants 1947–1981. The numerator was limited to the subset of 258 MS (Group II) also immigrating in 1947 and later, and age 0–79 in 1981. The absolute risk of MS for these migrants to the four states entering at age 0–14 was 22/100,000, significantly less than for all older age groups; age 15–39 immigrants had a risk of 54/100,000. Similar risk ratios for 0–14 versus 15–39 by state were 31 versus 61 (NSW), 29 versus 44 (QLD), 11 versus 50 (SA), 15 versus 51 (WA).


  • Historical and Clinical Perspectives of the Expanded Disability Status Scale

    by John F. Kurtzke

    Background: The measurement of neurologic impairment in multiple sclerosis (MS) is of importance in treatment trials and course of illness. Methods: This review describes the rationale underlying the formation and use of a bifid rating system, the (Expanded) Disability Status Scale (DSS) and the Functional Systems (FS). Results: All signs found at neurologic examination in MS can be consolidated into 8 mutually exclusive FS: pyramidal, cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral and other, each of which, save ‘other’, is given ordinal grades from 0 to 5 or 6. Each FS correlates with the DSS, a step scale from 0 (normal) to 10 (death due to MS), which is an overall measure of neurologic abnormality. Dividing steps 1–9 each into 2 gives the Expanded DSS. The FS and DSS were used in an Army series to describe neurologic status at first diagnosis and over the first 20 years of illness. DSS severity at 5 years after onset, but not earlier, was highly predictive of later severity. Conclusions: Combination of the (Expanded) DSS and FS has been used successfully to assess impairment for natural history and treatment studies in MS.


  • Origin of DSS: to present the plan

    by J F Kurtzke

    The Disability Status Scale for multiple sclerosis was the direct result of World War II, in which 16.4 million persons served in the US military. Thereafter academic medicine enabled the modernization of the Veterans Administration in patient care, research, and training. Under the GI Bill, I attended Cornell University Medical College, where there was an intensive course in neurological diagnosis requiring detailed recording of positive and negative findings. This was used in junior and senior clinical clerkships and residency training, all of which I took at the Bronx VA Hospital. During my residency we assessed a possible treatment for MS, which required a comparison group and a means of measuring change. The former comprised the records of over 300 MS patients, whose neurological deficits were then consolidated into mutually exclusive Functional Systems, each with grades for severity. As rank-order scales they could not be summed or compared directly, but they were used as the basis for the DSS, which ranged from 0 (normal) to 10 (death due to MS). This scale was later expanded into the EDSS by halving each step 1 through 9. This bifid system is applicable to all patients with MS regardless of type or severity of neurological impairment.